SpletGet the LIVE share price of Turning Point Therapeutics Inc(TPTX) and stock performance in one place to strengthen your trading strategy in US stocks. ... Market Cap: $3.80B: P/B … SpletFinancial Metrics. NASDAQ:TPTX financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, …
Market Cap Explained FINRA.org
Splet16. avg. 2024 · Turning Point Therapeutics (TPTX) has a Smart Score of 8 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. ... Enterprise Value/Market Cap N/A. Enterprise Value/Revenue N/A. Enterprise Value/Gross Profit N/A. Enterprise Value/Ebitda N/A. Price Target Upside … SpletYou can view TPTX vs its competitors side by side income and expenses, growth rates, profitability, stock performance and different valuation ratios. Stocks Features Premarket Trading After Hours Trading Market Movers 52-Week Highs & Lows Stock Order Imbalance Unusual Stock Volume Morning Report Company Events. Market Action Lists Top ... donald a schon reflective practice
TPTX Stock Financial Analysis - Turning Point Therapeutics Inc …
SpletTurning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung … SpletGet real-time Turning Point Therapeutics (TPTX) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing. Splet10. apr. 2024 · PRE 14Afalse00016744160001674416crsp:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMemberecd:PeoM... city of berkeley public works department